Kronos Bio (KRON)
(Delayed Data from NSDQ)
$1.02 USD
-0.03 (-2.86%)
Updated May 10, 2024 03:59 PM ET
After-Market: $1.01 -0.01 (-0.98%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
KRON 1.02 -0.03(-2.86%)
Will KRON be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KRON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KRON
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
KRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates
Other News for KRON
Optimistic Buy Rating for Kronos Bio Amid Positive KB-0742 Trial Progress and Expanding Oncology Pipeline
Kronos Bio GAAP EPS of -$0.50 misses by $0.08, revenue of $2.52M
Kronos Bio Reports First-Quarter 2024 Financial Results
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
Kronos Bio reports Q1 EPS (50c), consensus (42c)